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37.2% for high cost-sharing; p0.001). CONCLUSIONS: Patients in plans with no
cost-sharing have greater adherence and are less likely to discontinue treatment in
the 12-month period following DMT initiation. These results suggest that patients
with MS are sensitive to the financial costs associated with DMT and may make
treatment decisions based on this burden. Manufacturer co-pay assistance pro-
grams designed to reduce patient financial burden were not considered in this
analysis. Therefore, these results may underestimate the effects of benefit design
on medication adherence and persistence.
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OBJECTIVES: Since launch, HTA agencies from Germany, France and UK have re-
peatedly reviewed the use of Alzheimer’s disease (AD) treatments and issued rec-
ommendations, which have changed over time. The aim of this study was to un-
derstand the drivers of agency decisions and whether these too have changed over
time. METHODS: We reviewed HTA appraisals by IQWIG, HAS and NICE for three
acetylcholinesterase inhibitors (AChEI) donepezil, galantamine, rivastigmine and
memantine, an NMDA receptor antagonist from marketing authorisation to today
and identified arguments leading to recommendations. RESULTS: Between 1997
and 2002, the EMA approved donepezil, rivastigmine and galantamine for mild to
moderate AD and memantine for moderate to severe AD. We identified 2 multiple
technology assessments (MTA) and 3 single technology assessments (STA) by
IQWIG, 1 MTA and 16 STAs from HAS and 3 MTAs from NICE. Germany: IQWIG
ascribed the AChEI class a modest clinical benefit. Following two negative assess-
ments of memantine, the decision was reversed based on post-hoc analysis of
initial registration studies. France: HAS initially assigned all treatments an impor-
tant clinical added value (AMSR II) acknowledging high innovation. Later HAS re-
viewed the compounds in a new comparative setting (after withdrawal of tacrine)
and assigned only a minor clinical added value (ASMR IV). UK: NICE recommended
AChEIs in 2001, restricted their use in 2006 and in 2011 again recommended them,
while memantine received two negative recommendations followed by a positive
recommendation. The last review was based on additional data from randomized
clinical trials and the Assessment Group’s model demonstrating delay to
institutionalisation. CONCLUSIONS: The agencies revised assessments based on
post-marketing data. Differing national approaches led to different decisions:
IQWIG emphasises patient relevant benefit, HAS the clinical added value versus
similar medicinal products and NICE cost-effectiveness. Although agency deci-
sions changed, decision drivers were consistent across evaluations.
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OBJECTIVES: To quantify annual drug costs and hospitalization rates (HR) of adult
refractory focal epilepsy patients in Germany. METHODS: We retrospectively esti-
mated the annual HR and medication for refractory focal epilepsy patients based
on the NeuroTransData epilepsy database (input from 79neurologists, 34centers,
1240patients). Inclusion criteria (at least 1year of disease history; documentation
and treatment period of at least 6months; treatment with at least 1anitepileptic
drug [AED] in patient history; at least 1seizure during 6months of monitoring) led to
the identification of 70 patients. Average ambulatory daily therapy costs among all
prescribed drugs included were based on public prices (2011) considering claw-
backs and average dosing (real world setting [RWS] vs. daily defined dosing [DDD]).
HR were based on number of patients hospitalized. RESULTS: On average 2.1AEDs
per patient were prescribed, mainly generic drugs or branded drugs close to loss of
patent protection. Average daily costs per prescribed drug ranged from 0.65€ (Val-
proate) to 9.51€ (Lacosamid). Daily drug costs per patient ranged between 7.01€
(RWS) and 6.16€ (DDD). Annual total drug costs per patient were on average
2,557.44€. An ambulatory consultation rate of 2.1visits per patient within 6months
was recorded. Average HR was 44%, taking into account various reasons: 56% emer-
gency, 20% new adjustment for medication, 18% documentation of seizure, 4%
rehabilitation, 2% pre-surgical diagnostics. Mean duration was 34.9 (CI: 20.2-49.6;
median 17.8) days per patient hospitalized. Due to the potential selection bias and
the low number of analysed patients these results must be seen as indicative.
CONCLUSIONS: A 44% HR and a high average number of inpatient days (1month)
within 1year point to an unmet need for treatment optimization in refractory focal
epilepsy patients. It indicates that patients receiving combination therapy of con-
ventional drugs are often not well controlled, supporting the consideration of using
more innovative drugs.
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OBJECTIVES: Several disease-modifying therapies (DMTs) including IFNB-1b have
been approved for patients with multiple sclerosis (MS) to delay disease progres-
sion and reduce the incidence of relapses. Fingolimod, the first oral formulation of
DMT, was recently approved in several nations around the world including Ger-
many. This study aims to conduct a cost-minimization analysis to estimate the
cost impact of MS treatment with Fingolimod versus INFB-1b in Germany from the
societal perspective.METHODS:A Markov model is developed to follow the natural
history MS patients from time of diagnosis through disease progression and up to
20 years. MS patients receive either IFNB-1b or Fingolimod treatment but share the
same efficacy on disease progression and relapse rate due to the absence of head-
to-head comparison data. Fingolimod patients are assumed to have 10% higher
treatment adherence due to the oral formulation. In the model, DMTs costs (IFNB-
1b: €19,444/year and Fingolimod: €30,584/year) are based on AVP pharmacy retail
price, while other cost items are estimated from published literatures or local
databases. Main model outcomes include direct costs, indirect costs, and total
costs. All costs are inflated to 2010 Euros and discounted annually at 5%. RESULTS:
In the short-term analysis, Fingolimod costs additional €8,929 per patient in one
year and €29,550 per patient in 5 years compared to IFNB-1b. Long-term analysis (20
years) shows that cost savings associated with IFNB-1b is €41,593 per patient,
which mainly occurs when MS patients are still receiving treatment. The cost
advantages of IFNB-1b in the long-term analysis are attributed to its lower drug cost
(€50,342 vs. €92,873), serious adverse events management (€6.7 vs. €102.4), and
clinical monitoring (€8.8 vs. €438.2). CONCLUSIONS: Compared to Fingolimod, MS
treatment with INFB-1b leads to substantial cost savings from both societal and
payer perspectives in Germany, with similar treatment effectiveness.
PND65
DESCRIBING AND COMPARING UTILITY FROM EQ-5D AND SF-6D IN A
HUNTINGTON’S DISEASE POPULATION
Clay E1, Perthame E2, Maman K2, Dorey J3, Toumi M4
1Creativ Research, Paris, France, 2Creativ-Ceutical, Paris, France, 3Creativ Ceutical, Paris, France,
4University of Lyon, Lyon, France
OBJECTIVES: The SF-6D and the EQ-5D are two widely used questionnaires to
generate utility scores. The objective of this study is to describe and compare
utilities derived from EQ-5D and SF-6D in Huntington’s disease population.
METHODS:We used data from Euro-HDB, a multicenter cross-sectional study con-
ducted in France, Italy, Poland and Germany. In several subpopulations, with dif-
ferent degrees of severity, we used paired-samples t-test to identify significant
differences and calculated the Pearson’s correlation between SF-6D and the EQ-5D
utilities. RESULTS: The overall sample included 278 patients: 96 from France, 32
from Gemany, 103 from Italy and 47 from Poland. For the overall population, mean
utility scores were significantly different (EQ-5D: 0.34 (sd0.446); SF-6D: 0.62
(sd0.135); p0.0001). However values were strongly correlated (r 0.79, p0.001).
This difference was also significant when considering subpopulations (as discrim-
inated with score of clinical motor scale, and depression scale), with higher values
for SF-6D. The difference between EQ-5D and SF-6D utility scores was higher in
severe population than in moderate for most of the studied criteria (severe motor
impairment: EQ-5D: 0.62; SF-6D: 0.69; moderate motor impairment: EQ-5D: 0.00;
SF-6D: 0.51). The SF-6D scores distribution was found to be approximately normal
whereas the EQ-5D distribution was negatively skewed. CONCLUSIONS: In our
study, EQ-5D tends to generate lower scores in all Huntington’s disease subpopu-
lations. EQ-5D appears to be more sensitive than SF-6D. The choice of utility mea-
sure is likely to have a strong impact on incremental cost-effectiveness ratios of
interventions slowing the progression of Huntington’s disease.
PND66
CROSS-CULTURAL ADAPTATION AND VALIDATION OF THE BRAZILIAN
VERSION OF THE FATIGUE SEVERITY SCALE (FSS)
Toledo FO, Junior WM, Speciali JG, Sobreira CFDR
Sao Paulo University, Ribeirao Preto, Sao Paulo, Brazil
OBJECTIVES: The aim was to perform a cross-cultural adaptation and validation of
the Fatigue Severity Scale (FSS) for use in Brazilian patients with myopathy and
who complains of precocious muscular fatigue. METHODS: The FSS presents nine
items measured on a Likert scale ranging from 1 (completely disagree) to 7 (com-
pletely agree), where higher scores indicate higher level of fatigue. The process of
cross-cultural adaptation included: two independent translations for Portuguese
spoken in Brazil; the development of a consensual translated version; application
in a pilot group (n14) of patients with myopathy; evaluation by an expert com-
mittee for content validation; a back-translation by one bilingual translator whose
native tongue was English, but who was fluent in Brazilian Portuguese. The two
English versions (original and back translated) were analyzed by two of the authors
and a final Brazilian version was obtained. Twenty one patients with muscular
disease following at the outpatient clinic from a University Hospital answered the
Brazilian version of the FSS, the visual analogue scale (VAS) and the Chalder fatigue
questionnaire (CFQ). The following analyses were performed: exploratory factorial
analysis; internal consistency (Cronbach’s alpha); construct validity through of the
correlation with VAS and CFQ (physical and mental components). RESULTS: The
FSS scale obtained in the process of cross cultural adaptation was comprehensible
to individuals in the pilot population. The twenty one patients who participate in
the validation process were aged 21 to 65 years. The exploratory factor analysis
determined one factor, as the original version. Reliability analysis indicated satis-
factory internal consistency (0.93). Construct validity of the FSS (total score) with
VAS and CFQ demonstrated moderate correlations (0.60 and physical0.56, respec-
tively). The FSS didn=t correlate with mental component of the CFQ (0.31).
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